Skip to content
EyeQ Formulation™
 
Elevating the near vision experience
 
The only FDA-approved eye drop with the lowest effective concentration of pilocarpine for optimal results1–3
 
Lowest effective concentration of pilocarpine with 0.4% (4 mg/mL) of this active ingredient4

 


Near-neutral pH solution increases bioavailability, helping to make it effective at a minimum dose5,6

 


Dual lubricating agents (HA and HPMC) to enhance eye comfort1

 


Preservative-free solution1

Qlosi EyeQ Formulation™ maintains an optimal pupil size of 2mm–3mm for enhanced visual acuity. Studies have shown that this range increases depth of focus while minimizing the risk of diffraction7

HA=sodium hyaluronate; HPMC=hydroxypropyl methylcellulose

See how EyeQ Formulation™ delivers results

Explore efficacy

Important Safety Information

Expand

Indication and Usage

 

Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

 

Important Safety Information

Contraindications

Hypersensitivity

 

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

 

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

 

Qlosi is not recommended to be used when iritis is present.

 

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.

 

Avoid touching the tip of the vial to the eye or any other surface.

 

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

 

Please see full Prescribing Information here: qlosi.com/prescribing-information

References

  1. Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals.
  2. VUITY PI [package insert]. North Chicago, IL: AbbVie Inc.
  3. LENZ Therapeutics Corporate Presentation. November 2024.
  4. Holland E, Karpecki P, Fingeret M, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  5. Anderson RA, Cowle JB. Influence of pH on the effect of pilocarpine on aqueous dynamics. Br J Ophthalmol. 1968;52:607-611
  6. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci. 1988;77(9):771-775. doi:10.1002/jps.2600770911
  7. Xu R, Thibos L, Bradley A. Effect of Target Luminance on Optimum Pupil Diameter for Presbyopic Eyes. Optom Vis Sci. 2016;93(11):1409-1419. doi:10.1097/OPX.0000000000000963